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Thrombophilic mutations and risk of
retinal vein occlusion
INTRODUCTION
Retinal vein occlusion (RVO) is a major cause of visual impairment
and blindness, especially in the elderly(1-2). Coagulation abnormalities,
changes in blood vessel walls and systemic conditions such as hyper-
tension, atherosclerosis and diabetes mellitus seem to be associated with
RVO(1-2). However, in many cases none of these factors are present, and the
question of hidden risk factors is raised.
Three highly prevalent mutations have been described in association
with thrombosis: factor V Leiden (FV 1691A)(3), the prothrombin variant
(PT 20210A)(4) and homozygosity for the thermolabile methylenetetra-
hydrofolate reductase (MTHFR 677TT)(5). These mutations increase the
risk of thrombosis through different mechanisms. It is well established that
factor V Leiden and PT 20210A are associated with an increased risk of
venous thrombosis(6-7). The MTHFR 677TT has also been studied, with
controversial results(8-11). The risk associated with these mutations varies
with the topography of venous thrombosis(12-14). In the case of RVO, the
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Purpose: The association of retinal vein occlusion and hereditary throm-
bophilia abnormalities is not established, with controversial results in the
literature. This study investigates the association between retinal vein
occlusion and three thrombophilic mutations: factor V 1691A (factor V
Leiden), prothrombin 20210A (PT 20210A) and homozygous methy-
lenetetrahydrofolate reductase 677T (MTHFR 677TT). Methods: 55
consecutive retinal vein occlusion patients and 55 controls matched by
age, gender and race, were tested for the presence of the following
mutations: factor V Leiden, PT 20210A and MTHFR 677TT. The fre-
quencies of the three mutations in cases and controls were compared.
Results: Factor V Leiden was found in 3.6% of patients and in 0% of
controls; PT 20210A was found in 1.8% of patients and 3.6% of controls,
(matched-pair odds ratio, 0.5; 95% confidence interval, 0.04 to 5.51);
MTHFR 677TT was found in 9% of patients and 9% of controls (matched-
pair odds ratio, 1; 95% confidence interval, 0.92 to 3.45). Arterial
hypertension was more frequent in patients than controls (matched-pair
odds ratio, 3.4; 95% confidence interval, 1.25 to 9.21). Conclusions: This
study suggests that thrombophilic mutations are not risk factors for RVO.
Routine investigation of hereditary thrombophilia in these patients is
not justified.
ABSTRACT
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role of these mutations is still unclear. The purpose of this
study was to evaluate if these mutations are risk factors for
retinal vein occlusion.
METHODS
Patients
A 1:1 matched case-control study was performed, inclu-
ding all patients referred to the hemostasis laboratory betwe-
en October 1999 and January 2005 with RVO. A total of 55
patients were included.
Controls
A pool of controls was established, consisting of indi-
viduals brought in by the patients, not genetically related, as
well as other patients from the hospital with no history of
thrombosis (formally enquired). Each case was matched to a
control according to age (±3 years), gender, and racial back-
ground (defined as Caucasian or Afro-Brazilian based on the
familial background and phenotypic characteristics as de-
termined by the interviewers).
Therefore, 55 case-control pairs were available for the
analysis.
Laboratory tests
After signing an informed consent, patients and controls
had a 10 mL blood sample collected in EDTA for DNA ana-
lysis. Genomic DNA was isolated from peripheral blood leu-
kocytes by a standard procedure. Detection of factor V Lei-
den was carried out by the polymerase chain reaction (PCR)
of a fragment of exon 10 of the factor V gene, digested by
MnlI(3). For the identification of PT 20210A, DNA was am-
plified and digested by HindIII(4). The MTHFR C677T was
detected by HinfI cleavage of a PCR-amplified product(5).
Risk factors
Hypertension, diabetes mellitus, and the three mutations
(factor V Leiden, PT 20210A and MTHFR 677TT) were as-
sessed as potential risk factors for retinal thrombosis. Hy-
pertension was defined by either the use of antihypertensive
drugs or by a diastolic blood pressure >90 mmHg or a systo-
lic blood pressure >140 mmHg on two consecutive measu-
rements in different days. Diabetes mellitus was defined on
the basis of whether the subject was using insulin or glucose-
lowering drugs or on criteria of the American Diabetes As-
sociation, namely a fasting plasma glucose ≥126 mg/dL (7.0
mmol/L) or 2-h postload glucose ≥200 mg/dL (11.1 mmol/L)
during an oral glucose tolerance test.
Statistical analysis
The matched-pair odds ratios and the 95% confidence
intervals (CI) were calculated from the number of discordant
pairs. The tests were performed using Epi-Info (Centers for
Disease Control and Prevention, USA) and Win Episcope 2.0.
RESULTS
The series included 32 women (58%) and 23 men (42%),
with a median age of 61.5 years (range 17-83 years). Thirty-
seven (67%) patients were Caucasians and 18 (33%) were
African-Brazilians. Thirty-one patients (56%) and nineteen
controls (35%) had hypertension (matched-pair odds ratio,
3.4; 95% confidence interval, 1.25 to 9.21). The frequency of
diabetes mellitus was the same (9%) in the two groups.
The distribution of the three genotypes in patients and
controls is shown in table 1. A hereditary thrombophilia was
found in 7 patients (13%): factor V Leiden (in heterozygous)
in 2 patients, PT 20210A (in heterozygous) in 1 patient and
MTHFR 677TT (in homozygous) in 5 patients (one patient
had both factor V Leiden and MTHFR 677TT). One patient
with FV Leiden also had deep venous thrombosis of lower
limbs. None of the patients, including this one, was using
anticoagulant treatment at the moment of the RVO. A here-
ditary thrombophilia was also present in 7 controls (13%): PT
20210A in 2 and MTHFR 677TT in 5. Only factor V Leiden
was more frequent in patients than in controls (3.6% versus
0%). The risk of RVO was not significantly higher in indi-
viduals presenting either one of the three mutations.
Twenty-three patients were younger than 60 years. The
prevalence of mutations in this younger group was not higher
compared to older subjects (one patient had factor V Leiden
and two presented MTHFR 677TT).
There were 3 patients (9%) with mutations among the 33
patients with central retinal vein occlusion, and 4 (18%)
among the 22 patients with occlusion in a branch of the retinal
vein, but these prevalences were not significantly different
from the control group.
DISCUSSION
Retinal vein occlusion is a common disorder in elderly
patients. The Blue Mountains Eye Study found a prevalence
of retinal venous occlusive disease of 0.7% in individuals
younger than 60 years, 1.2% in individuals aged 60 to 69
years, and 4.6% in individuals older than 80 years(15). The
identification of risk factors would be an important step
towards the prevention of this potentially ominous disorder.
The frequency of thrombophilic mutations in patients
presenting RVO in previous studies range from 0% to 17%
for the factor V Leiden(16-20), from 0% to 10% for PT
20210A(16,19,21-24) and from 3% to 19% for MTHFR 677TT(25-30).
These differences may be related to the racial background,
selection of the control group, and study design. In the pre-
sent study, the frequencies of FV1691A, PT20210A and
MTHFR were 4%, 2% and 9% respectively.
Studies investigating the presence of activated protein C
resistance or factor V Leiden have suggested their potential
role in RVO(16,25,29). Recently, a study(31) also suggested that
the presence of factor V Leiden increases the risk of neo-
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vascular complications in patients presenting central RVO.
However, despite being the thrombophilic abnormality most
frequently associated with RVO, most studies have failed to
show a role for this mutation in RVO(17-19,22,26,32). In the present
study, factor V Leiden was the only mutation with a higher
frequency in patients than in controls (3.6% versus 0%). In a
previous report, a prevalence of 1% for factor V Leiden in a
normal cohort of Brazilians was observed(12). Therefore, the
increased prevalence in patients with RVO cannot be ruled
out, and this matter requires further study.
A higher prevalence of the prothrombin variant
PT20210A in patients with central retinal vein occlusion was
also reported(23), but has not been confirmed in most stu-
dies(26,28-30,33). In the present study, this mutation was not more
frequent among patients.
Higher levels of plasmatic homocysteine in patients with
RVO have also been reported(34-35) and two case-control stu-
dies identified MTHFR 677TT as a potential risk factor for
RVO(32,36). Nevertheless, most studies did not confirm the role
of this mutation in RVO(26,28-30). In the present study, the same
frequency of MTHFR 677TT was found in cases and controls.
Even when analyzing separately in central retinal vein
occlusion (CRVO) and branch retinal vein occlusion (BRVO),
the mutations did not represent a risk for RVO. Occlusion of
the central retinal vein occurs at a variable distance posterior
to the lamina cribosa, where the central retinal vein shares a
common adventitial sheath with the central retinal artery(37-39).
On the other hand, BRVO is associated with arteriosclerotic
changes in the retinal arterioles and the resultant thickening
appears to cause compression of adjacent veins, a process
that may be aggravated because the two vessels are confined
within a common adventitial sheath(40).
In this study, it is also noteworthy that the mutations did
not represent a risk for RVO in patients younger than 60 years.
Some limitations of this study must be mentioned. The
clinical status of patients with arterial hypertension and dia-
betes mellitus was not available in all cases. In some cases,
the angiographic exam was not performed in the acute phase
of the OVR. Finally, the definition of race in the Brazilian
population is always controversial. Unlike any other country
in the Americas, the Portuguese colonization in Brazil was
marked by intense racial mixing of European, African and
Indian groups, with gradual loss of traditional phenotypic
and genotypic boundaries. In the present study, individual
were classified as Caucasians or Afro-Brazilians by a simple
and quite subjective examination by the interviewers. Howe-
ver, any interpretation of race in the Brazilian context must
be met with substantial reservation.
CONCLUSION
In summary, our results show no indication that the mu-
tations PT 20210A or MTHFR 677TT have a role in predis-
posing patients to RVO. The prevalence of Factor V Leiden
was also low in the present study, but its role in RVO de-
mands further study. Routine screening for these mutations
in patients with RVO is not indicated.
RESUMO
Objetivos: A associação entre oclusão venosa retiniana e
trombofilias hereditárias não está estabelecida, com resulta-
dos controversos na literatura. O presente estudo investiga a
associação entre a oclusão venosa retiniana e três mutações
trombofílicas: fator V 1691A (fator V Leiden), protrombina
20210A (PT 20210A) e mutação C677T do gene da metileno-
tetra-hidro-folato redutase (MTHFR 677TT). Métodos: Cin-
quenta e cinco pacientes portadores de oclusão venosa re-
tiniana e 55 controles pareados por idade, sexo e raça foram
testados para a presença das seguintes mutações: fator V
Leiden, PT 20210A e MTHFR 677TT. As freqüências das três
mutações em casos e controles foram comparadas. Resulta-
dos: Fator V Leiden foi encontrado em 3,6% dos pacientes e
em 0% dos controles; PT 20210A foi encontrada em 1.8%
dos pacientes e em 3,6% dos controles, (odds ratio, 0,5; 95%
IC, 0,04 to 5,51); MTHFR 677TT foi encontrada em 9% dos
pacientes e em 9% dos controles (odds ratio, 1; 95% IC, 0,92
to 3,45). Hipertensão arterial foi encontrada mais freqüen-
temente em pacientes do que em controles (odds ratio, 3,4;
95% IC, 1,25 to 9,21). Conclusões: O presente estudo sugere
que mutações trombofílicas não são fatores de risco para
oclusão venosa retiniana. A investigação rotineira para trom-
bofilias hereditárias neste grupo de pacientes não é indicada.
Descritores: Oclusão da veia retiniana; Fatores de risco;
Trombofilia; Fator V; Protrombina; Metilenotetraidrofolato
redutase (NADPH2)
Table 1. Frequency of genotypes in patients with retinal vein occlusion and controls
Patients (55) Controls (55) Odds ratio (CI 95%)
n (%) n (%)
Factor V Leidena 2 (3.6) 0 (0) NQ
Prothrombin 20210Ab 1 (1.8) 2 (3.6) 0.5 (0.04 – 5.51)
MTHFR 677TTc 5 (9.0) 5 (9.0) 1.0 (0.29 – 3.45)
a
= 2 discordant patient-control pairs, in which the patient had factor V Leiden and the control did not; b= 3 discordant patient-control pairs: in 1 the patient had PT20210A
and the control did not; in 2 the control had PT20210A and the control did not; c= 10 discordant patient-control pairs: in 5 the patient had MTHFR 677TT and the control
did not; in other 5 the control had MTHFR 677TT and the patient did not; NQ= not quantifiable. CI: confidence interval
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